Biogen Inc (NASDAQ: BIIB) has a price-to-earnings ratio of 14.98x that is above its average ratio. Additionally, the 36-month beta value for BIIB is -0.07. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 8 rating it as “overweight,” 11 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIIB is 144.59M and currently, short sellers hold a 2.16% ratio of that float. The average trading volume of BIIB on November 14, 2024 was 1.18M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BIIB) stock’s latest price update
Biogen Inc (NASDAQ: BIIB)’s stock price has dropped by -1.48 in relation to previous closing price of 168.28. Nevertheless, the company has seen a loss of -4.94% in its stock price over the last five trading days. zacks.com reported 2024-11-12 that The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
BIIB’s Market Performance
BIIB’s stock has fallen by -4.94% in the past week, with a monthly drop of -13.45% and a quarterly drop of -17.78%. The volatility ratio for the week is 2.11% while the volatility levels for the last 30 days are 2.40% for Biogen Inc The simple moving average for the last 20 days is -7.23% for BIIB’s stock, with a simple moving average of -21.35% for the last 200 days.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with Morgan Stanley repeating the rating for BIIB by listing it as a “Equal-Weight.” The predicted price for BIIB in the upcoming period, according to Morgan Stanley is $204 based on the research report published on October 31, 2024 of the current year 2024.
Needham gave a rating of “Buy” to BIIB, setting the target price at $300 in the report published on February 14th of the current year.
BIIB Trading at -11.60% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.21% of loss for the given period.
Volatility was left at 2.40%, however, over the last 30 days, the volatility rate increased by 2.11%, as shares sank -12.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.11% lower at present.
During the last 5 trading sessions, BIIB fell by -4.94%, which changed the moving average for the period of 200-days by -32.90% in comparison to the 20-day moving average, which settled at $178.71. In addition, Biogen Inc saw -35.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 431 shares at the price of $204.22 back on Sep 03 ’24. After this action, Singhal Priya now owns 5,316 shares of Biogen Inc, valued at $88,019 using the latest closing price.
Singhal Priya, the Officer of Biogen Inc, proposed sale 431 shares at $204.22 during a trade that took place back on Sep 03 ’24, which means that Singhal Priya is holding shares at $88,019 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.72 for the gross margin
The net margin for Biogen Inc stands at 0.17. The total capital return value is set at 0.08. Equity return is now at value 10.47, with 5.72 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 0.34. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is 9.61.
Currently, EBITDA for the company is 2.38 billion with net debt to EBITDA at 1.11. When we switch over and look at the enterprise to sales, we see a ratio of 2.91. The receivables turnover for the company is 4.73for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In conclusion, Biogen Inc (BIIB) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
